Get ready for the big loss

[anonymous]

Why hasn’t anyone discussed the bio similar for tysabri and the double step edits put on vumerity. viebacher can trim a lot of fat to make up for the lost revenue. Tysabri was compared to placebo in phase 3 for bio similar approval and results were identical. Wake up folks. The gig is up because zuranolone won’t generate
Much until 2024. biogen finally has deal with real managed markets competition and won’t be able to respond. Oh wait theexpanded part d will save the day good luck to those that don’t survive the cut .

 

[anonymous]

Why hasn’t anyone discussed the bio similar for tysabri and the double step edits put on vumerity. viebacher can trim a lot of fat to make up for the lost revenue. Tysabri was compared to placebo in phase 3 for bio similar approval and results were identical. Wake up folks. The gig is up because zuranolone won’t generate
Much until 2024. biogen finally has deal with real managed markets competition and won’t be able to respond. Oh wait theexpanded part d will save the day good luck to those that don’t survive the cut .

Tysabri Biosimilar will not have much impact. Zuranalone will be approved and. Available late summer. Biogen will be fine. Lev will get approved and supply huge revenues 2024 and beyond. Future is very bright!!!

 

[anonymous]

From Matthew Schrag

 

[anonymous]

Viehbacher is just getting warmed up. Fasten your seatbelts!! The fun hasn't started yet.

 

[anonymous]

Yeah, There is no new revenue stream and companies cant charge 80 -100lk per year for MS drugs and certainly no antidepressant will generate $500 millioni n first year. Another AA dream. Lots of cuts coming!
Every dept will be trimmed. Dont listen to your managers. Biogen has been boated for long time and time to streamline operations.

 

[anonymous]

From Matthew Schrag

https://twitter.com/schrag_matthew/status/1597860185426784257?t=wgDkyG0sC8B2K144fkarcA&s=19

 

[anonymous]

Why hasn’t anyone discussed the bio similar for tysabri and the double step edits put on vumerity. viebacher can trim a lot of fat to make up for the lost revenue. Tysabri was compared to placebo in phase 3 for bio similar approval and results were identical. Wake up folks. The gig is up because zuranolone won’t generate
Much until 2024. biogen finally has deal with real managed markets competition and won’t be able to respond. Oh wait theexpanded part d will save the day good luck to those that don’t survive the cut .

Didn’t Matt save MS?

 

[anonymous]

Oh shit - first the CEO, then all of us. It’s over folks

 

[anonymous]

No way will they touch MS.

 

[anonymous]

Yeah, There is no new revenue stream and companies cant charge 80 -100lk per year for MS drugs and certainly no antidepressant will generate $500 millioni n first year. Another AA dream. Lots of cuts coming!
Every dept will be trimmed. Dont listen to your managers. Biogen has been boated for long time and time to streamline operations.

YES!!!!!!!